Ultime notizie per IGC Pharma (AMEX:IGC) Azioni

IGC Pharma

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

IGC Pharma Inc

INTEGRATED CYBR SOLUTIONS by INTEGRATED CYBER SOLUTIONS INC.

Integrated Cyber Solutions Inc

<a href="https://www.marijuanamoment.net/newly-elected-republican-senate-majority-leader-opposes-marijuana-legalization-rescheduling-and-industry-banking-access/">https://www.marijuanamoment.net/newly-elected-republican-senate-majority-leader-opposes-marijuana-legalization-rescheduling-and-industry-banking-access/</a>
Senate Republicans on Wednesday <a href="https://www.marijuanamoment.net/every-gop-senate-majority-leader-candidate-opposes-marijuana-legalization/">elected a new majority leader who not only opposes legalizing marijuana</a> but has also called for a reversal of the Biden administration's plan to reschedule cannabis and has criticized Democrats for working to increase the industry's access to banking services.
Thune, who defeated Sens. John Cornyn (R-TX) and Rick Scott (R-FL) in an election for the leadership slot, joined other GOP lawmakers in a letter in July <a href="https://www.marijuanamoment.net/gop-lawmakers-push-justice-department-to-reverse-course-on-marijuana-rescheduling/">challenging the current administration's marijuana rescheduling push</a>, urging that the policy proposal be trashed.
The rescheduling rule "fails to provide adequate science and data to support moving marijuana to schedule III and should not have been signed or published," the letter Thune signed says, calling it "irresponsible" for federal health officials to "make this determination when emerging research shows that there are significant health concerns associated with marijuana use."
The letter details Thune's and other Republican lawmakers' concerns about marijuana's health effects, suggesting that there is a "clear association between cannabis use and psychosis, anxiety, cognitive failures, respiratory adverse events, cancer, cardiovascular outcomes and gastrointestinal disorders."
It also claims that "sexual disfunction was twice as high in men who used marijuana" and that "marijuana use among veterans with PTSD was associated with worse PTSD symptoms, more violent behavior, and alcohol use."
Beyond criticizing cannabis use and policy reform, the letter Thune signed further calls into question whether marijuana has any medical value.
"Medical marijuana dispensaries sell edibles and vapes that come in flavors like passion raspberry, blueberry calm, wild cherry, and sour apple," it says. "Pretending that these products are medicine that can treat health conditions is doing a disservice to Americans."
"It remains the case that marijuana has no currently accepted medical use," Thune and his Republican colleague wrote. "The fact that states have labeled marijuana as ‘medicine' does not change the nature of the drug… We urge you to withdraw this proposal and maintain marijuana as a schedule I drug."
Separately, as Senate Democrats moved to advance a marijuana legalization bill in 2021, Thune <a href="https://twitter.com/JulieNBCNews/status/1384583108410978312">said</a> that cannabis reform is "something we'll probably have to grapple with here." But he's consistently opposed even modest proposals to allow marijuana industry banking.
Earlier this year, Thune said attaching cannabis banking legislation to an aviation bill would be "a non-starter," <a href="https://www.bloomberg.com/news/newsletters/2024-05-01/pot-industry-banking-bill-still-in-limbo-but-not-dead-yet">noting</a> that Republican&nbsp; opposition to the idea is "very strong."
He <a href="https://www.congress.gov/congressional-record/volume-166/issue-96/senate-section">called</a> the then-Democratic-controlled House's proposal to include marijuana banking reform in a large-scale coronavirus relief bill "crazy stuff" in 2020, complaining in a floor speech that the text of the underlying legislation mentions "cannabis" more times than "jobs."
"In case Democrats didn't realize, Americans aren't suffering from a lack of cannabis right now," Thune <a href="https://www.thune.senate.gov/public/index.cfm/2020/5/thune-senate-focused-on-american-people-while-house-is-distracted-by-liberal-agenda">said</a> in a speech on the Senate floor. "They're suffering from a lack of employment."
He also said that Democrats' push to advance a marijuana legalization bill was a "great illustration of the gap in priorities."
"While Republicans are continuing to negotiate on COVID relief, Democrats are holding votes on a Tiger King bill &amp; legalizing cannabis," he said. "Let's get serious &amp; do our job for Americans."
Back in 2014, Thune said that while he understands that "people have strong opinions on both sides of this debate, I do not support legalizing the use of marijuana."
"Currently, the medical benefits from the use of marijuana are still inconclusive, and I believe that we must be careful not to increase the availability of marijuana and the use of marijuana for non-medical reasons," the senator <a href="https://www.facebook.com/permalink.php?story_fbid=1423720604579857&amp;id=1374412469510671">said</a> in a constituent letter. "However, I support the development of alternative medications that will provide relief to patients without opening the door to substance abuse."
The next year, he called legalization a "dangerous path," <a href="https://vote.norml.org/politicians/398">adding</a> that voters who enacted the reform in Colorado are "going to pay a price for it."
In 2021, Thune acknowledged that cannabis is an "area that's still evolving, and our country's views on it are evolving," <a href="https://www.politico.com/news/2021/06/27/republicans-weed-496390">adding</a> that "how we deal with it nationally I think is still an open question."
"Medical's getting big — the recreational not as big yet, but it's growing — and there'll be more initiatives on the ballot," he said.
For what it's worth, voters in Thune's home state of South Dakota approved a marijuana legalization initiative at the ballot in 2020, but it was overturned by the state Supreme Court. Voters subsequently <a href="https://www.marijuanamoment.net/south-dakota-voters-reject-marijuana-legalization-ballot-initiative-after-third-attempt-from-advocates/">rejected legalization proposals in 2022 and 2024</a>.

Macro Economic Events

News

Politics

Legal

Economics

General

AKAN

CRON

GRWG

IMCC

LFLY

MAPS

MSOS

SNDL

TLRY

'Newly Elected Republican Senate Majority Leader Opposes Marijuana Legalization, Rescheduling And Industry Banking Access' - Marijuana Moment

IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now available as part of the IMS Spotlight Series.
In the interview, Ram Mukunda discusses IGC's strategic expansion into metabolic and neurological markets, specifically addressing the potential of GLP-1 agonists in both Alzheimer's and weight loss therapies. Mukunda also provides updates on IGC Pharma's lead candidate, IGC-AD1, which is currently in Phase 2 trials for treating agitation in Alzheimer's dementia and is progressing toward additional trials to explore its potential as a disease-modifying treatment.
The interview underscores IGC's approach to leveraging artificial intelligence to diversify its pipeline, targeting both neurodegenerative and metabolic disorders to maximize patient impact.
To read the full interview, please visit: <a href="https://pr.report/41tx">Expanding Our Portfolio: IGC Pharma's Strategic Growth in Alzheimer's and Weight Loss Therapies</a>

Biotech

IGC Pharma Announces Publication Of IMS Spotlight Interview With CEO Ram Mukunda Highlighting Strategic Expansion In Alzheimer's And Weight Loss Therapies

<a href="https://www.marijuanamoment.net/legislative-committee-in-ireland-calls-for-marijuana-legalization-and-decriminalization-of-all-illicit-drugs/">https://www.marijuanamoment.net/legislative-committee-in-ireland-calls-for-marijuana-legalization-and-decriminalization-of-all-illicit-drugs/</a>
After lawmakers in Ireland <a href="https://www.marijuanamoment.net/irelands-government-proposes-nine-month-delay-on-marijuana-legalization-bill-vote-calling-for-special-committee/">delayed a vote on marijuana legalization earlier this year</a> in favor of further studying the issue, a special legislative committee on drug policy has published an interim report with nearly 60 recommendations, calling for changes such as the limited legalization of marijuana and the decriminalization of personal use and possession of all illegal drugs.
The new report, released on Tuesday, is the product of the Oireachtas Joint Committee on Drugs Use, which was formed to consider cannabis legalization and other drug policy issues following the release of a <a href="https://www.marijuanamoment.net/as-irish-lawmakers-prepare-to-debate-marijuana-bill-prime-minister-pledges-to-examine-drug-decriminalization-as-recommended-by-citizen-commission/">citizen commission report in January that recommended broadly decriminalizing drugs</a>&nbsp;and implementing harm reduction programs.
Gino Kenny, the chair of the committee and a member of Ireland's lower house of parliament, <a href="https://www.irishexaminer.com/news/arid-41501180.html">told</a> Irish Examiner that the proposal could allow cannabis clubs where members can purchase small amounts of marijuana grown on a nonprofit basis, which <a href="https://www.marijuanamoment.net/german-officials-approve-countrys-first-marijuana-social-club-since-legalization-took-effect/">some other European countries permit</a>, but may also allow for broader commercial legalization.
"It's important that this is implemented," Kenny told the paper, emphasizing his perspective that the government should adopt a "health-led approach" to drug use.
&nbsp;
Indeed, many of the 59 recommendations from the special committee focus on shifting the paradigm around drug control from one of punishment and stigma to one of health and harm reduction. That's the core of the first six recommendations laid out in the committee's description of its interim report, which includes findings that "the stigmatisation of drug use and the shaming of drug users are a source of significant harm" and that "the goal of drug policy should be to reduce harm and eliminate stigma."
To that end, it says, "the decriminalization of possession for personal use should apply equally to all illicit drugs." And while "people should be offered all supports and health resources that are required," it adds, "no person should be criminalised for not availing of a supportive intervention."
When it comes to marijuana, the committee is calling on health and justice officials to "undertake a body of research into how a regulated drug market could operate in Ireland beginning with cannabis, and how Ireland can incorporate and implement the learnings of other jurisdictions that have taken positive steps in this regard."
The report specifies that the country should consider reforms "with particular reference to Spain, Malta, and Germany in the development of an Irish not for profit regulated cannabis market."
The body is also calling for expansion of the country's medical marijuana program "to ensure that more people affected by chronic illness can access cannabis in circumstances where other treatments have failed to relieve symptoms."
The recommendations also advise that local authorities and An Garda Síochána—the country's national police force—"are supported and empowered in strongly discouraging and reducing consumption in public areas." The committee suggested that "specific trauma and harm reduction training be provided to An Garda Síochána and local authorities, to inform their work with individuals and communities affected by drug misuse and addiction."
Kenny, the committee chair, noted that the body's <a href="https://www.oireachtas.ie/en/press-centre/press-releases/20241022-joint-committee-on-drugs-use-publishes-interim-report-with-59-recommendations/">recommendations</a> are "very clear that the supply and sale of drugs should remain illegal" and acknowledged that drugs can cause "huge damage" to individuals, families and communities, especially among already disadvantaged groups. But he said the committee was in broad agreement that criminalizing substances is the wrong approach.
"There's still a lot to look at of course, but between the work done by the Committee and the Citizens' Assembly, it's clear that there is a consensus that criminalising and prosecuting the use of drugs for personal drug use is a waste of money and is very detrimental to anyone convicted," he said in a statement.
After months of study, he added, "there's no excuse for a new Government to say that issues around the decriminalisation of drugs for personal use haven't been discussed properly. Both the Citizens' Assembly and the Oireachtas Joint Committee on Drugs Use have looked at the issue in detail."
When the committee was first being formed, Ryan McHale, executive committee member of the Irish drug policy reform organization Crainn, told Marijuana Moment that he felt the extra step was a "delay tactic from the Irish Government," which he called "disappointing given the clear calls from the Citizens' Assembly and overwhelming public support for the measure."
"The government are aware of the overwhelming support which is why they didn't outright oppose the bill like they did in 2013, which was the last attempt to liberalize cannabis laws," McHale said. "While there appears to be a shift from government in terms of changing Ireland's drug laws, they have not yet committed to any substantial legal change."
"This delay will mean that hundreds of people will be criminalized for personal possession of cannabis while the Irish government ponder the political effectiveness of reform," he added. "We cannot wait anymore and the Citizens' Assembly have been clear in their calls for change to the harmful status quo."
TD Paul Murphy said the government's proposed delay is "simply an attempt to kick the can down the road."
"They talk about a health led approach to drugs," he said. "Now it's time to walk the walk."
The cannabis legalization bill from Kenny that prompted the committee's formation was first introduced in 2022.
Ireland's taoiseach—or prime minister—Leo Varadkar <a href="https://www.marijuanamoment.net/as-irish-lawmakers-prepare-to-debate-marijuana-bill-prime-minister-pledges-to-examine-drug-decriminalization-as-recommended-by-citizen-commission/">told lawmakers earlier this year that he agrees prohibition doesn't work</a>, as evidenced by prohibition periods in Ireland that created illicit markets with "impure" alcohol products.
"In my view, drug use and misuse by individuals should be seen primarily as a public health issue and not a criminal justice matter," Varadkar said. "I certainly think that shaming people and blaming people and criminalizing people isn't an effective policy."
The Citizens' Assembly on Drugs Use considered marijuana legalization as part of its work last year, but a <a href="https://www.marijuanamoment.net/irish-citizens-panel-votes-to-recommend-decriminalizing-drug-possession-but-marijuana-legalization-falls-one-vote-short/">recommendation to enact the reform came up short by one vote</a>.
A year ago, the citizens' group posted summaries of 36 policy recommendations online—the culmination of what the body's chair, Paul Reid, called "the most comprehensive, wide-ranging, and representative discussion on all aspects of drugs use and drugs policy that has ever taken place in Ireland."
The group's overarching message, Reid said in a statement at the time, was that lawmakers must "take a much more ambitious and progressive approach to dealing with drugs in Ireland."
"Ultimately, it will be up to the Oireachtas to implement what the Assembly has called for," he said, referring to Ireland's national parliament. "But if they do, this will not only change the national policy and approach, it will also change people's lives. For the better."

Global

iShares MSCI Ireland Capped Investable Market Index Fund

EIRL

"Legislative Committee In Ireland Calls For Marijuana Legalization And Decriminalization Of 'All Illicit Drugs'" - Marijuana Moment

Lawmakers Urge DEA To Finalize Marijuana Rescheduling Proposal

<h3>Gainers</h3>
<ul>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock moved upwards by 38.8% to $13.82 during Monday's regular session. The company's market cap stands at $488.1 million. </li>
<li>Kezar Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) shares moved upwards by 36.58% to $0.74. The company's market cap stands at $54.2 million. </li>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) stock moved upwards by 32.73% to $0.47. The company's market cap stands at $35.5 million. </li>
<li>Xenetic Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBIO#NASDAQ">XBIO</a>) stock rose 27.82% to $4.87. The company's market cap stands at $7.5 million. </li>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) stock increased by 16.44% to $4.03. The company's market cap stands at $483.5 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) stock moved upwards by 16.35% to $0.59. The market value of their outstanding shares is at $22.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock decreased by 28.8% to $0.46 during Monday's regular session. The company's market cap stands at $6.0 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares declined by 27.4% to $0.67. The company's market cap stands at $6.9 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock decreased by 25.87% to $0.36. The company's market cap stands at $2.6 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares decreased by 20.04% to $1.48. The company's market cap stands at $8.7 million. </li>
<li>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) shares fell 19.87% to $16.07. The market value of their outstanding shares is at $864.0 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 18.81% to $0.36. The company's market cap stands at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APDN

BNOX

CAPR

ALPS ETF Trusthen & Steers Global Realty Majors ETF

HCWB

PRME

PRTA

PSTV

XBIO

12 Health Care Stocks Moving In Monday's Intraday Session

WIIM

Shares of cannabis stocks are trading higher following a report suggesting that Vice President Harris wants to legalize marijuana.

<a href="https://www.marijuanamoment.net/kamala-harris-says-we-need-to-legalize-marijuana-for-first-time-as-democratic-presidential-nominee/">https://www.marijuanamoment.net/kamala-harris-says-we-need-to-legalize-marijuana-for-first-time-as-democratic-presidential-nominee/</a>
Vice President Kamala Harris says it's time to legalize marijuana—marking the first time she has publicly discussed her position on cannabis since becoming the Democratic presidential nominee.
"I just feel strongly, people should not be going to jail for smoking weed," she said in an interview with the All the Smoke podcast that was released on Monday. "And we know historically what that has meant and who has gone to jail."
"Second, I just think we have come to a point where we have to understand that we need to legalize it and stop criminalizing this behavior," Harris told hosts Matt Barnes and Stephen Jackson, who are former NBA players.
"Actually this is not a new position for me," Harris, who sponsored a federal cannabis legalization bill as a U.S. senator, said. "I have felt for a long time we need to legalize it. So that's where I am on that."
Until now, Harris had not made her position on marijuana part of her current campaign for the White House.
Earlier this month, <a href="https://www.marijuanamoment.net/marijuana-legalization-is-an-issue-for-the-states-vp-candidate-tim-walz-says-adding-that-electing-democrats-to-congress-will-boost-cannabis-reform/">Democratic vice presidential nominee Tim Walz said he thinks marijuana legalization is an issue that should be left to individual states</a>, adding that electing more Democrats to Congress could also make it easier to pass federal reforms like cannabis banking protections.
"I think it's an issue for the states on some of those, and that's the way the states have done it," Walz, who is Minnesota's governor and previously served in Congress, said, dodging a reporter's direct question about national cannabis legalization.
During that interview, Walz highlighted two incremental reform issues: medical marijuana access for veterans who receive healthcare through the Department of Veterans Affairs (VA) as well as passage of federal legislation that would ease restrictions for banks that due business with marijuana companies.
If Democrats take control of both houses of Congress, he said, those matters might be easier to address.
"There's work to be done nationally around the banking issue," he said in the Spectrum News&nbsp;interview&nbsp;that was posted on September 14, "and I think that's something that if we get a working Congress who actually wants to solve some issues—when we have the Democrats in charge of the House and the Senate—then we can start to see if some of those things make sense."
Harris, for her part, has spoken in favor of federal legalization in the past, for example at&nbsp;<a href="https://www.marijuanamoment.net/kamala-harris-says-we-need-to-legalize-marijuana-for-first-time-since-joining-biden-ticket-signaling-potential-shift-ahead-of-election/">a closed-door roundtable event with cannabis pardon recipients</a> in March. In her previous run for president, Harris also&nbsp;<a href="https://www.marijuanamoment.net/harris-backed-broad-drug-decriminalization-during-2020-election-run-resurfaced-aclu-questionnaire-shows/">backed full federal decriminalization for simple drug possession</a>.
Meanwhile former President Donald Trump said recently during his campaign for a second term that he now supports federal marijuana rescheduling and marijuana banking access.
"As President, we will continue to focus on research to unlock the medical uses of marijuana to a Schedule 3 drug, and work with Congress to pass common sense laws, including safe banking for state authorized companies, and supporting states rights to pass marijuana laws, like in Florida, that work so well for their citizens," Trump posted to social media earlier this month.
<a href="https://www.marijuanamoment.net/trump-says-florida-marijuana-legalization-ballot-measure-will-be-very-good-for-the-state-adding-that-medical-use-is-absolutely-amazing-for-patients/">Trump also recently discussed the medical benefits</a>&nbsp;of cannabis and said legalization would be "very good" for Florida, which will consider the reform at the ballot box in November's election.
The Harris–Walz campaign, however, has&nbsp;<a href="https://www.marijuanamoment.net/harris-campaign-accuses-trump-of-lying-about-marijuana-reform-support-but-again-declines-to-detail-her-own-platform/">accused Trump of lying about his support for marijuana reform</a>—arguing that his "blatant pandering" runs counter to his administration's record on cannabis.
Following Trump's recent announcement of support for the Florida cannabis legalization ballot measure, the Democratic campaign has been working to remind voters that while in office, <a href="https://www.marijuanamoment.net/harris-accuses-trump-of-brazen-flip-flops-on-marijuana-as-former-president-endorses-florida-legalization-measure/">Trump "took marijuana reform backwards."</a>
In a memo from a senior campaign spokesperson, the Harris-Walz campaign accused Trump of "brazen flip flops" on cannabis, saying it's one of the Republican former president's "several bewildering ‘policy proposals' that deserve real scrutiny."
The posturing by the presidential candidates comes amid an ongoing process of moving marijuana to the less-restrictive Schedule III of the Controlled Substances Act (CSA).
The Department of Health and Humans Services (HHS) this spring recommended moving the drug to Schedule III, but the action has faced resistance from the Drug Enforcement Administration (DEA), which has&nbsp;<a href="https://www.marijuanamoment.net/dea-schedules-hearing-on-marijuana-rescheduling-proposal-delaying-final-rule/">scheduled a hearing on the proposal for December 2</a>—after the presidential election,&nbsp;<a href="https://www.marijuanamoment.net/dea-pushing-marijuana-rescheduling-past-election-is-incredibly-disappointing-congressman-says-as-stakeholders-react-to-hearing/">raising concerns that the process will not be completed</a>&nbsp;until after a new president is inaugurated.
Meanwhile, Trump also recently&nbsp;<a href="https://www.marijuanamoment.net/trump-claims-harris-jailed-thousands-and-thousands-of-black-people-over-marijuana-but-her-actual-record-as-a-prosecutor-is-more-nuanced/">went after Harris over her prosecutorial record on marijuana</a>, claiming that she put "thousands and thousands of Black people in jail" for cannabis offenses—but the full record of her time in office is more nuanced.
Trump's line of attack, while misleading, was nonetheless notable in the sense that the GOP presidential nominee implied that he disagrees with criminalizing people over marijuana and is moving to leverage the idea that Harris played a role in racially disproportionate mass incarceration.
As president, Trump largely stayed true to his position that marijuana laws should be handled at the state-level, with no major crackdown on cannabis programs as some feared after then-Attorney General Jeff Sessions rescinded the Obama era federal enforcement guidance. In fact, Trump&nbsp;<a href="https://www.marijuanamoment.net/gop-senator-reveals-what-trump-said-about-jeff-sessionss-anti-marijuana-moves/">criticized the top DOJ official and suggested the move should be reversed</a>.
While he was largely silent on the issue of legalization, he did tentatively endorse a bipartisan bill to&nbsp;<a href="https://www.marijuanamoment.net/trump-says-he-supports-senate-marijuana-legislation/">codify federal policy respecting states' rights to legalize</a>.
That said, on several occasions he released signing statements on spending legislation stipulating that he&nbsp;<a href="https://www.marijuanamoment.net/trump-issues-signing-statement-on-medical-marijuana-provision-of-funding-bill/">reserved the right to ignore a long-standing rider</a>&nbsp;that prohibits the Justice Department from&nbsp;<a href="https://www.marijuanamoment.net/trump-says-he-can-ignore-medical-marijuana-protections-passed-by-congress/">using its funds to interfere with state-legal medical marijuana programs</a>.
Before President Joe Biden bowed out of the race, his campaign made much of the president's mass cannabis pardons and rescheduling push,&nbsp;<a href="https://www.marijuanamoment.net/biden-smokes-trump-on-marijuana-policy-campaign-says-after-presidents-rescheduling-announcement/">drawing a contrast with the Trump administration's record</a>. The Harris campaign so far has not spoken to that particular issue, and the nominee has yet to publicly discuss marijuana policy issues since her own campaign launched.

Econ #s

"Kamala Harris Says 'We Need To Legalize' Marijuana For First Time As Democratic Presidential Nominee" - Marijuana Moment

<h3>Gainers</h3>
<ul>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) stock moved upwards by 10.7% to $0.39 during Friday's after-market session. The company's market cap stands at $29.6 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares rose 10.03% to $5.92. The market value of their outstanding shares is at $3.0 million. </li>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) stock rose 5.86% to $0.74. The company's market cap stands at $111.5 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock rose 5.07% to $0.23. The company's market cap stands at $18.6 million. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) stock moved upwards by 4.72% to $0.31. The market value of their outstanding shares is at $155.9 million. </li>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) shares rose 4.66% to $0.62. The market value of their outstanding shares is at $36.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) stock fell 9.6% to $1.8 during Friday's after-market session. The market value of their outstanding shares is at $45.9 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) stock declined by 6.53% to $1.11. The company's market cap stands at $40.4 million. As per the news, the Q4 earnings report came out today. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock decreased by 6.1% to $0.46. The market value of their outstanding shares is at $35.7 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) stock declined by 6.07% to $0.19. The market value of their outstanding shares is at $10.6 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) stock decreased by 5.66% to $2.67. The company's market cap stands at $417.9 million. </li>
<li>Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) shares decreased by 5.41% to $0.21. The market value of their outstanding shares is at $8.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCLI

ELEV

ESLA

EYEN

GANX

Kintara Therapeutics, Inc. - Common Stock

KTRA

OPTN

TCBP

VIRX

ZJYL

12 Health Care Stocks Moving In Friday's After-Market Session

IGC Pharma shares are trading higher after a Form 4 filing showed that company director James P. Moran purchased 588,235 shares of common stock at $0.34 per share.

Insider Trades

IGC Pharma From4 Filing Shows Company Director James P Moran Bought 588,235 Shares Of Common Stock At A Price Of $0.34/Share

<a href="https://cannabiswire.com/news/2024/09/26/for-the-first-time-national-agriculture-regulators-group-grapples-with-cannabinoid-hemp/">https://cannabiswire.com/news/2024/09/26/for-the-first-time-national-agriculture-regulators-group-grapples-with-cannabinoid-hemp/</a>
&nbsp;

"National Agriculture Regulators Group Grapples With Intoxicating Hemp For The First Time; FDA's Norm Birenbaum Says Existing FDA Regulatory Frameworks 'Do Not Apply To Large Segments Of The Market, Like Inhalable Products, Where We Have Tremendous Concerns'" - Cannabis Wire

<a href="https://www.marijuanamoment.net/dea-calls-for-massive-increases-in-psilocybin-ibogaine-and-thc-manufacturing-this-year-to-meet-research-demands/">https://www.marijuanamoment.net/dea-calls-for-massive-increases-in-psilocybin-ibogaine-and-thc-manufacturing-this-year-to-meet-research-demands/</a>
The Drug Enforcement Administration (DEA) is proposing a dramatic increase in its 2023 production quotas for marijuana compounds and psychedelics like psilocybin and ibogaine to "support research and clinical trials" into the substances.
DEA wants to nearly double the amount of psilocybin, psilocyn and delta-9 THC that's manufactured compared to initial levels set for this year, while quintupling how much ibogaine is produced. It also wants 23 times as much of "other tetrahydrocannabinol," raising the quota from 15,000 grams to 350,000 grams for 2023.
The agency had already increased its initial quota for various controlled substances, including cannabis and psychedelics, late last year when it finalized the numbers. But now, in a notice published in the Federal Register on Tuesday, DEA said that more significant changes are warranted.
For psilocybin, the proposed new quota is 15,000 grams, rather than 8,000 grams as previously set for 2023. DEA also wants 24,000 grams of the psychedelic compound psilocyn, double its prior 12,000-gram quota.
The now-increased initial 2023 levels for both of the "magic mushroom" components already represented significant increases from those set for prior years, demonstrating the ongoing heightened level of interest in researching psychedelics over time.
DEA is also proposing to manufacture 150 grams of ibogaine—five times the amount it called for in December 2022.
While the agency didn't change its 6.7 million-gram quota for marijuana for the year, it is now calling for the manufacturing of 628,460 grams of delta-9 THC, rather than 384,460 grams—a 63 percent increase.
For all other tetrahydrocannabinol, DEA wants 350,000 grams, a notable increase from its prior 15,000-gram quota—a massive 2,233 percent increase.
The proposed increases, which are subject to a 30-day public comment period starting on Tuesday, comes in the context of an ongoing administrative review into the scheduling status of cannabis that DEA is actively carrying after receiving a recommendation from the U.S. Department of Health and Human Services (HHS) to <a href="https://www.marijuanamoment.net/top-federal-health-agency-releases-highly-redacted-marijuana-scheduling-recommendation-letter-to-dea/">move marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA)</a>.
It also comes as experts await a <a href="https://www.marijuanamoment.net/after-latest-clinical-trial-mdma-therapy-for-ptsd-is-on-track-for-fda-consideration-next-year/">potential federal approval for certain psychedelics like psilocybin and MDMA</a> as therapeutics for the treatment of serious mental health conditions.
The updated quotas reflect "the estimated medical, scientific, research, and industrial needs of the U.S., for lawful export requirements, and for the establishment and maintenance of reserve stocks," DEA <a href="https://www.federalregister.gov/public-inspection/2023-23931/proposed-adjustments-to-the-aggregate-production-quotas-for-schedule-i-and-ii-controlled-substances">said</a> in its new quota increase notice.
"DEA is proposing increases to the [aggregate production quotas] for the following schedule I substances: all other tetrahydrocannabinol, delta-9-tetrahydrocannabinol, ibogaine, psilocybin, and psilocyn," it said. "These proposed increases are to support research and clinical trials by DEA-registered schedule I researchers. These proposed increases demonstrate DEA's support for research with schedule I controlled substances."
 DEA's prior "final" quotas that were published late last year already <a href="https://www.marijuanamoment.net/dea-proposes-dramatic-increases-in-marijuana-and-psychedelics-production-in-2023-for-research/">contained increases compared to its initial proposal</a>, with <a href="https://www.marijuanamoment.net/dea-proposes-even-higher-2023-production-quotas-for-psychedelics-like-mdma-and-psilocyn/">the agency calling for the manufacturing of more psychedelic compounds</a> such as MDMA, psilocyn and 5-MeO-DMT.
This year's 6.7 million-gram quota for marijuana is more than double DEA's final <a href="https://www.marijuanamoment.net/dea-again-boosts-2022-production-goals-for-psychedelics-like-psilocybin-mdma-and-dmt/">cannabis quota for 2022, which was 3.2 million grams.</a>&nbsp;<a href="https://www.marijuanamoment.net/dea-boosts-psilocybin-mdma-and-dmt-production-levels-again-in-final-quotas-for-2021/">It was 2 million grams for 2021</a>.
Growing millions of grams of cannabis may be easier since&nbsp;<a href="https://www.marijuanamoment.net/dea-finally-breaks-federal-marijuana-grower-monopoly-with-two-new-companies-harvesting-cannabis-approved-by-agency/">DEA finally authorized additional manufacturers</a>&nbsp;at the beginning of the year. Those approved cultivators are now able to apply for&nbsp;<a href="https://www.marijuanamoment.net/top-federal-drug-agency-seeking-marijuana-grower-able-to-cultivate-and-analyze-4-million-grams-of-cannabis/">a contract to be federal marijuana suppliers</a>&nbsp;for study purposes under the National Institute on Drug Abuse (NIDA).
The agency has touted its Schedule I drug production quotas as evidence that is supports rigorous research into the substances, but it's faced criticism from advocates and scientists over actions that are viewed as antithetical to promoting studies.
Following pushback, DEA recently retreated on&nbsp;<a href="https://www.marijuanamoment.net/dea-abandons-proposal-to-ban-two-more-psychedelics-after-being-challenged-by-scientists/">a proposed ban on psychedelic compounds</a>&nbsp;that scientists say have research value.
That marked another win for scientific community, coming just one month after DEA&nbsp;<a href="https://www.marijuanamoment.net/dea-cancels-proposed-ban-of-five-psychedelics-giving-scientists-more-time-to-research-therapeutic-benefits/">abandoned separate plans to place five tryptamine psychedelics in Schedule I</a>.
Meanwhile, a federal appeals court recently ruled against DEA in a <a href="https://www.marijuanamoment.net/federal-appeals-court-rules-against-dea-in-psilocybin-rescheduling-lawsuit-brought-by-doctor-who-wants-to-give-psychedelic-to-cancer-patients/">lawsuit over a Washington State doctor's petition to reschedule psilocybin</a>. The court said DEA failed to explain its reasoning when it denied the petition, and it ordered the agency to provide a more complete justification.
With respect to the agency's marijuana scheduling review, a coalition of 31 bipartisan House lawmakers has sent a letter to DEA Administrator Anne Milgram, urging her to <a href="https://www.marijuanamoment.net/31-bipartisan-house-lawmakers-push-dea-to-consider-merits-of-marijuana-legalization-as-it-completes-scheduling-review/">take into account congressional and state marijuana legalization efforts</a> as it completes that assessment. They also criticized the limitations of simple rescheduling as they push for complete a complete removal of marijuana from the CSA.
The letter serves as a counterbalance to other recent messages DEA has received from congressional opponents of reform and former DEA and White House drug czars who&nbsp;<a href="https://www.marijuanamoment.net/marijuana-rescheduling-would-supersize-the-industry-former-dea-heads-and-white-house-drug-czars-warn-biden-administration/">argue that even moving marijuana to Schedule III would go too far</a>.
A coalition of 14 Republican congressional lawmakers recently&nbsp;<a href="https://www.marijuanamoment.net/14-gop-congressional-lawmakers-tell-dea-to-keep-marijuana-in-schedule-i-and-reject-top-health-agencys-recommendation/">urged DEA to "reject" the top federal health agency's recommendation to reschedule marijuana</a>&nbsp;and instead keep it in the most restrictive category under the CSA.
Meanwhile, two GOP senators, including the lead Republican sponsor of&nbsp;<a href="https://www.marijuanamoment.net/watch-live-a-u-s-senate-committee-is-voting-on-a-marijuana-banking-bill/">a marijuana banking bill that cleared a key committee last month</a>, recently filed new legislation to&nbsp;<a href="https://www.marijuanamoment.net/gop-senators-file-bill-to-block-biden-marijuana-rescheduling-effort-without-congressional-approval/">prevent federal agencies from rescheduling cannabis&nbsp;without tacit approval from Congress</a>.

CMPS

CYBN

DRUG

ENVB

MNMD

SEEL

'DEA Calls For Massive Increases In Psilocybin, Ibogaine And THC Manufacturing This Year To Meet Research Demands'  - Marijuana Moment

IGC Pharma Says IGC-AD1 Demonstrated Potential To Modify Tau And Improve Spatial Memory

IGC Pharma Advances Proprietary Alzheimer's Treatment IGC-AD1 Toward Clinical Trials, Targeting Amyloid Plaques With Promising Safety Profile And Potential To Reduce Plaque Aggregation By 20%

Ratings for IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $3.5, a high estimate of $3.75, and a low estimate of $3.25. Observing a 5.11% increase, the current average has risen from the previous average price target of $3.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1725364819_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of IGC Pharma among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward Woo</td>
<td>Ascendiant Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$3.75</td>
<td>$3.50</td>
</tr>
<tr>
<td>Edward Woo</td>
<td>Ascendiant Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$3.50</td>
<td>$3.25</td>
</tr>
<tr>
<td>James Molloy</td>
<td>Alliance Global Partners</td>
<td>Announces</td>
<td>Buy</td>
<td>$3.50</td>
<td>-</td>
</tr>
<tr>
<td>Edward Woo</td>
<td>Ascendiant Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.25</td>
<td>$3.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IGC Pharma. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IGC Pharma compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of IGC Pharma's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of IGC Pharma's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/IGC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on IGC Pharma analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About IGC Pharma</h2>
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
<h3>IGC Pharma's Economic Impact: An Analysis</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Negative Revenue Trend: Examining IGC Pharma's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -50.99% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: IGC Pharma's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -874.26%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): IGC Pharma's ROE excels beyond industry benchmarks, reaching -31.29%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): IGC Pharma's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -23.2%, the company may face hurdles in achieving optimal financial performance.
Debt Management: IGC Pharma's debt-to-equity ratio is below the industry average. With a ratio of 0.04, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Analyst Verdict: IGC Pharma In The Eyes Of 4 Experts

Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) with a Buy and raises the price target from $3.5 to $3.75.

Price Target

Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $3.75

IGC Pharma's Preclinical Research Highlights IGC-1C's Potential As A Multi-Pathway Treatment Targeting Tau Protein And GLP-1 Receptor, Offering Promising Approaches For Neurodegenerative Diseases And Weight Loss; AI Model Identifies IGC-1C And IGC-1A As GLP-1 Receptor Agonist Candidates

IGC Pharma Says IGC-1A Has Been Identified As A Potential GLP-1 Agonist

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

'Trump Endorsing Florida Marijuana Legalization Initiative Would 'Guarantee Victory,' Top Ally Roger Stone Says' - Marijuana Moment

IGC Pharma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) reported its financial results Thursday for the first fiscal quarter of 2025 ended June 30, 2024. The Maryland-based pharmaceutical company disclosed revenue of $272,000, representing a decrease of 51% compared to approximately $555,000 in the first fiscal quarter of 2024.
The company attributes the decrease in revenue to the completion of its legacy infrastructure project in India and some white-label project in the U.S., both of which comprised approximately 50% of the June 2023 revenue.
"The first quarter of fiscal 2025 was marked by significant milestones in our Alzheimer's research portfolio, underscoring our strategic focus on our innovations," Ram Mukunda, CEO of IGC Pharma, stated. "The progress in our Phase 2 clinical trial for IGC-AD1, highlighted by interim data demonstrating a clinically significant reduction in agitation, validates the immense potential of our lead investigational drug. Additionally, the positive pre-clinical outcomes for TGR-63 underscore its promise as a transformative therapy for Alzheimer's, advancing us closer to delivering a novel solution for this critical unmet need. We are strategically positioned to continue expanding our clinical trial footprint and patient enrollment throughout fiscal 2025 as we continue to drive toward commercialization while maximizing operational efficiency and leveraging our unique vertically integrated model."
In April, IGC Pharma disclosed interim data from its Phase 2 clinical trial of IGC-AD1 for agitation in dementia&nbsp;<a href="https://www.benzinga.com/pressreleases/24/04/b38266079/igc-ad1s-interim-phase-2-data-show-a-reduction-in-alzheimers-agitation-at-week-two" target="_blank" rel="noreferrer noopener">associated with Alzheimer's</a>. The company said that its cannabinoid-based drug candidate provides fast relief with <a href="https://www.benzinga.com/general/biotech/24/04/38275005/igc-pharma-says-cannabinoid-based-drug-candidate-provides-fast-relief-with-fewer-side-effects-for">fewer side effects for Alzheimer's-associated agitation.</a>
Read Also: <a href="https://www.benzinga.com/general/health-care/24/03/37854695/exclusive-revolutionary-alzheimers-drug-by-igc-shows-early-success">EXCLUSIVE: Revolutionary Alzheimer&#8217;s Drug By IGC Shows Early Success</a>
<h2 class="wp-block-heading">Q1 FY2025 Financial And Operational Summary</h2>
<ul>
<li>Net loss amounted to $2.4 million, or $0.03 per share, compared to a net loss of $2.1 million, or $0.04 per share, in the same period last year.</li>
<li>Selling, general and administrative expenses reached $1.7 million, representing an increase of approximately $23,000, or 1%, compared to the three months ended June 30, 2023.</li>
<li>Research and development expenses were $899,000, representing an increase of approximately $142,000 or 19% compared to the three months ended June 30, 2023. The increase is primarily attributable to the progression of Phase 2 trials on IGC-AD1 and pre-clinical studies on the other small molecule assets. We anticipate increased R&amp;D expenses as the development of our other small molecule assets targeting Alzheimer's and the Phase 2 trial on Alzheimer's expand.</li>
<li>As of June 30, 2024, the company has not used any of the $12 million available under the Credit Agreement with O-Bank.</li>
</ul>
<h2 class="wp-block-heading">Price Action</h2>
IGC Pharma shares closed Thursday's market session 1.30% higher at $0.39 per share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40271940/trump-says-its-hard-to-have-people-all-over-the-jails-for-cannabis-offenses-as-he-hints-at-legal">Trump Says It&#8217;s &#8216;Hard To Have People All Over The Jails&#8217; For Cannabis Offenses As He Hints At Legalization</a></li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/01101836/CCC-Oct-24-Banner-1.gif" alt="CCC banner https://www.benzinga.com/events/cannabis-conference/" class="wp-image-470628" /></a></figure>
Photo: Courtesy of r.classen via Shutterstock

Cannabis

Earnings

IGC Pharma Revenue Declines 51% YoY Due To Completion Of Its Legacy Project In India, Highlights Important Milestones In Alzheimer's Research

IGC Pharma GAAP EPS of -$0.22 in-line, revenue of $1.35M beats by $0.11M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning!



Moving stocks this morning are earnings reports, insider buying, offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is rocketing more than 78% alongside heavy pre-market trading.</li>



<li>Senti Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/snti-stock-quote/">SNTI</a>) shares are soaring over 47% with strong early morning trading.</li>



<li>GlycoMimetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/glyc-stock-quote/">GLYC</a>) stock is surging more than 39% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318411360&amp;type=PDF&amp;symbol=GLYC&amp;cdn=8f7645b9da4ce31c36360d7737c007dc&amp;companyName=GlycoMimetics+Inc.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2024-06-24">alongside insider buying</a>.</li>



<li>Anew Medical (OTCMKTS:<a href="https://investorplace.com/stock-quotes/leas-stock-quote/">LEAS</a>) shares are gaining over 38% without any clear news this morning.</li>



<li>Nukkleus (NASDAQ:<a href="https://investorplace.com/stock-quotes/nukk-stock-quote/">NUKK</a>) shares are increasing more than 24% with strong pre-market trading.</li>



<li>Regis (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgs-stock-quote/">RGS</a>) stock is rising over 21% after announcing a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318412499&amp;type=PDF&amp;symbol=RGS&amp;cdn=4f01bbb678bba4ddafaac79f77ec0544&amp;companyName=Regis+Corporation&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-25">senior secured credit facility</a>.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) shares are heading close to 20% higher with heavy pre-market trading today.</li>



<li>Kaival Brands Innovations (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/">KAVL</a>) stock is jumping more than 17% <a href="https://www.nasdaq.com/press-release/kaival-brands-announces-closing-60-million-public-offering-2024-06-24">after closing a public offering</a>.</li>



<li>BioXcel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/btai-stock-quote/">BTAI</a>) shares are climbing over 13% on <a href="https://www.nasdaq.com/press-release/bioxcel-therapeutics-announces-positive-topline-results-post-marketing-requirement">topline results from a study</a>.</li>



<li>Captivision (NASDAQ:<a href="https://investorplace.com/stock-quotes/capt-stock-quote/">CAPT</a>) stock is up more than 12% on Tuesday morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) stock is plummeting over 25% on plans for a <a href="https://finance.yahoo.com/news/faraday-future-announces-plans-regaining-215900667.html">reverse stock split</a>.</li>



<li>Concord Medical Services (NYSE:<a href="https://investorplace.com/stock-quotes/ccm-stock-quote/">CCM</a>) shares are diving more than 22% after a massive rally yesterday.</li>



<li>Beyond Air (NASDAQ:<a href="https://investorplace.com/stock-quotes/xair-stock-quote/">XAIR</a>) stock is tumbling over 19% on <a href="https://finance.yahoo.com/news/beyond-air-inc-xair-reports-212503389.html">lackluster Q4 earnings</a>.</li>



<li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) shares are retreating more than 19% <a href="https://investorplace.com/2024/06/why-is-microalgo-mlgo-stock-up-113-today/">after rallying yesterday</a>.</li>



<li>SolarEdge Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sedg-stock-quote/">SEDG</a>) stock is taking an over 16% beating on a <a href="https://www.nasdaq.com/press-release/solaredge-technologies-inc-announces-proposed-private-offering-300-million">$300 million private offering</a>.</li>



<li>IGC Pharma (NYSEMKT:<a href="https://investorplace.com/stock-quotes/igc-stock-quote/">IGC</a>) shares are dropping more than 16% on its <a href="https://www.nasdaq.com/press-release/igc-reports-financial-results-fiscal-year-ended-march-31-2024-2024-06-24">latest earnings report</a>.</li>



<li>Oragenics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ogen-stock-quote/">OGEN</a>) stock is falling over 15% on a <a href="https://www.stocktitan.net/news/OGEN/oragenics-inc-announces-proposed-public-688vwqnwez4o.html">proposed public offering</a>.</li>



<li>DermTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) shares are decreasing nearly 12% after a <a href="https://www.nasdaq.com/press-release/dermtech-files-voluntary-chapter-11-protection-2024-06-18">recent bankruptcy filing</a>.</li>



<li>Professional Diversity (NASDAQ:<a href="https://investorplace.com/stock-quotes/ipdn-stock-quote/">IPDN</a>) stock is slipping more than 11% with recent weakness.</li>



<li>36KR (NASDAQ:<a href="https://investorplace.com/stock-quotes/krkr-stock-quote/">KRKR</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-june-25th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Argenx Se (ARGX – Research Report), IGC Pharma (IG...

Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), IGC Pharma (IGC) and Fresenius Medical Care AG & Co. KGaA (GB:0H9X)

India Globalization Capital GAAP EPS of -$0.03 in-line, revenue of $0.27M misses by $0.04M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
IGC Pharma (NYSEMKT:<a href="https://investorplace.com/stock-quotes/igc-stock-quote/">IGC</a>) just reported results for the first quarter of 2025.<ul><li>IGC Pharma reported earnings per share of -3 cents. This was above the analyst estimate for EPS of -4 cents.</li><li>The company reported revenue of $272,000.</li><li>This was 56.13% worse than the analyst estimate for revenue of $620,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/igc-stock-earnings-igc-pharma-for-q1-of-2025/">IGC Stock Earnings: IGC Pharma Beats EPS, Misses Revenue for Q1 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

IGC Stock Earnings: IGC Pharma Beats EPS, Misses Revenue for Q1 2025

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on an operational updat...

Rising High: RIV Capital provides update on revenue, synergy realization

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on earnings, an acquisi...

Rising High: Compass Pathways reports Q3 earnings

IGC Pharma (IGC) announced the publication of a new interview with CEO Ram Mukunda, now available as part of the IMS Spotlight Series.In the interv...

IGC Pharma announces publication of IMS Spotlight interview

In this edition of "Rising High," The Fly conducted an exclusive interview with Adam Wilks, Co-Founder and CEO of Carma HoldCo, a house of brands f...

Rising High: Exclusive talk with house of brands Carma HoldCo

ABBV

ALEC

AMRX

ARGX

ATAI

BTAI

CANN

CAPT

CNPOF

CNTMF

COYA

CURLF

CVSI

DMTK

FFIE

FFNTF

GLYC

GTBIF

IPDN

KAVL

KRKR

LEAS

MLGO

NCPL

NUKK

OGEN

RLMD

SAVA

SAVAW

SEDG

SHFS

SKYE

SNTI

TCNNF

VLCN

VREOF

XAIR

Screenshot 2024-05-08 at 6.04.45 PM

OSUKF

6.7 Million Americans Live With Alzheimer&#39;s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings

Screenshot 2024-03-19 at 5.39.00 PM

IGC Pharma Advances In Alzheimer&#39;s Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1

Press Releases

IGC Pharma Reports First Quarter Fiscal 2025 Results

IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

IGC Announces Results of its 2024 Annual Stockholders Meeting

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies

Comments

IGC Pharma

Notizie

Ultime notizie per IGC Pharma (AMEX:IGC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO